AAV9 Targets Cone Photoreceptors in the Nonhuman Primate Retina
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Transduction of retinal pigment epithelial cells with an adeno-associated viral vector (AAV) based on serotype 2 has partially corrected retinal blindness in Leber congenital amaurosis type 2. However, many applications of gene therapy for retinal blindness rely on the efficient transduction of rod and cone photoreceptor which is difficult to achieve with first generation vector technology. To address this translational need, we evaluated rod and cone photoreceptor targeting of 4 novel AAV capsids (AAV7, AAV9, rh.64R1 and rh.8R) versus AAV2 and AAV8 in a foveated retina. Eyes of 20 nonhuman primates were injected subretinally in the proximity of the fovea. While numerous vectors efficiently transduced rods, only AAV9 targeted cones both centrally and peripherally efficiently at low doses, likely due to the abundance of galactosylated glycans, the primary receptor for AAV9, on cone photoreceptors. We conclude AAV9 is an ideal candidate for strategies that require restoration of cone photoreceptor function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Quantitative analysis of tropism and transgene expression levels in the NHP eye. Cynomolgus macaques were injected with AAVs expressing 109 or 1010 GC per eye. Following necropsy at 4–5 month post injection, retinas were sectioned and analyzed for direct fluorescence. Data from a morphometric analysis in the RPE (A) and PR (B) layers is presented with the relative area of transduction on the left and an intensity scoring on the right. AAV2 and AAV8 data are historical data from an analogous, previously reported study [6] [a 109 GC injection was not performed for AAV2 (n/a)]. Eyes for which the injection failed as noted in Table 1 were excluded from this analysis. Data is presented as average and standard deviation.](https://figures.cochat.ai/paper-figures/9a765e4024d54a32b356231d26292d89/aav9-targets-cone-photoreceptors-in-the-nonhuman-primate-retina-figure-1.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“RPE cells can be targeted using AAV1, AAV4, or AAV6 vectors or with the engineered AAV2-7m8 vector, and photoreceptors and Müller glial cells are targeted by serotypes AAV2, AAV5, AAV6, AAV7, AAV8, and AAV9 as well as engineered AAV2-7m8 and AAV8BP2 vectors.56,112–116”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [115]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“RPE cells can be targeted using AAV1, AAV4, or AAV6 vectors or with the engineered AAV2-7m8 vector, and photoreceptors and Müller glial cells are targeted by serotypes AAV2, AAV5, AAV6, AAV7, AAV8, and AAV9 as well as engineered AAV2-7m8 and AAV8BP2 vectors.56,112–116”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [116]
Experimental — accuracy not yet measuredIn the citing paper
“However, AAV9 has been shown to be efficient in animal studies (Vandenberghe et al., 2013; Lee et al., 2018b; Ail et al., 2022).”
From AAV2 and AAV9 tropism and transgene expression in the mouse eye and major tissues after intravitreal and subretinal delivery (2023) · cites this paper as Vandenberghe et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“All human applications of AAV gene transfer to the retina, and most other target organs, have utilized vectors based on serotype 2 (AAV2) [7,8,9].”
BackgroundSelf-citationEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 1×
“All human applications of AAV gene transfer to the retina, and most other target organs, have utilized vectors based on serotype 2 (AAV2) [7,8,9].”
BackgroundSummerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406 · cited 1×
“AAV2 is known to utilize heparin sulfate proteoglycans as its primary receptor for cellular recognition [22].”
BackgroundClades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070 · cited 1×
“The distinct properties of AAV serotypes in terms of tropism and dosage thresholds in the retina and other organs motivated us to explore other natural AAV variants derived from novel viral clades identified in a biomining effort in our laboratory from human and NHP tissues [25,26].”
BackgroundSelf-citationHauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954 · cited 1×
“All human applications of AAV gene transfer to the retina, and most other target organs, have utilized vectors based on serotype 2 (AAV2) [7,8,9].”
BackgroundGenetic Reactivation of Cone Photoreceptors Restores Visual Responses in Retinitis Pigmentosa
Busskamp, V., Duebel, J., Balya, D., Fradot, M., Viney, T. J., Siegert, S., Groner, A. C., Cabuy, E., Forster, V., Seeliger, M., et al. (2010) · Science · doi:10.1126/science.1190897 · Cited by 642
(1998) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(97)00012-8 · Cited by 570 · cited 1×
“Retinitis pigmentosa (RP) primarily affects rod PR but can result in secondary abnormalities of cones [1].”
BackgroundHamel, C. P. (2007) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-2-7 · Cited by 449 · cited 1×
“Cone and cone-rod dystrophies such as Stargardt’s disease are characterized by a primary cone involvement, with possibly concomitant loss of rods [2].”
BackgroundKaludov, N., Brown, K. E., Walters, R. W., Zabner, J., & Chiorini, J. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.6884-6893.2001 · Cited by 427 · cited 1×
“Viral entry of AAV1, 4, 5, and 6 is initiated by sialylated glycoproteins [23,24].”
BackgroundWu, Z., Miller, E., Agbandje-McKenna, M., & Samulski, R. J. (2006) · Journal of Virology · doi:10.1128/jvi.00895-06 · Cited by 328 · cited 1×
“Viral entry of AAV1, 4, 5, and 6 is initiated by sialylated glycoproteins [23,24].”
Background
Research works printed but not linked: 1
- AH Milam, 1998, Histopathology of the human retina in retinitis pigmentosa, Prog Retin Eye Res, 17, 175
Cited by
Functional architecture of the retina: Development and disease
Hoon, M., Okawa, H., Della Santina, L., & Wong, R. O. L. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.06.003 · Cited by 585
Various AAV Serotypes and Their Applications in Gene Therapy: An Overview
Issa, S. S., Shaimardanova, A. A., Solovyeva, V. V., & Rizvanov, A. A. (2023) · Cells · doi:10.3390/cells12050785 · Cited by 313
Vector platforms for gene therapy of inherited retinopathies
Trapani, I., Puppo, A., & Auricchio, A. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.08.001 · Cited by 183
“, 2013) and AAV2/9 (Vandenberghe et al., 2013) were found to present the highest cone transduction”
BackgroundInfluentialNassi, J. J., Cepko, C. L., Born, R. T., & Beier, K. T. (2015) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2015.00080 · Cited by 155
“Serotypes vary in terms of the speed of onset of viral gene expression, with some of the serotypes being particularly slow, needing up to several weeks for the maximum number of cells to show evidence of infection (Vandenberghe et al., 2013).”
BackgroundControlling AAV Tropism in the Nervous System with Natural and Engineered Capsids
Castle, M. J., Turunen, H. T., Vandenberghe, L. H., & Wolfe, J. H. (2016) · Methods in Molecular Biology · doi:10.1007/978-1-4939-3271-9_10 · Cited by 151
“In nonhuman primate subretinal injections, AAV8 efficiently targets rod PRs [54], while AAV9 is superior for cone PRs and retains tropism for rod PRs [53].”
BackgroundInfluentialSelf-citationEvaluation of Dose and Safety of AAV7m8 and AAV8BP2 in the Non-Human Primate Retina
Ramachandran, P. S., Lee, V., Wei, Z., Song, J. Y., Casal, G., Cronin, T., Willett, K., Huckfeldt, R., Morgan, J. I. W., Aleman, T. S., et al. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.111 · Cited by 147
Self-citationGene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Triple Vectors Expand AAV Transfer Capacity in the Retina
Maddalena, A., Tornabene, P., Tiberi, P., Minopoli, R., Manfredi, A., Mutarelli, M., Rossi, S., Simonelli, F., Naggert, J. K., Cacchiarelli, D., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.019 · Cited by 128
Noninvasive gene delivery to foveal cones for vision restoration
Khabou, H., Garita-Hernandez, M., Chaffiol, A., Reichman, S., Jaillard, C., Brazhnikova, E., Bertin, S., Forster, V., Desrosiers, M., Winckler, C., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.96029 · Cited by 124
“Previous studies have shown that subretinal injection of AAV9 leads to efficient transgene expression in cones both centrally and peripherally at low doses, likely due to the abundance of galactosylated glycans, the primary receptor for AAV9, on cone photoreceptors (30, 35).”
BackgroundSlijkerman, R. W. N., Song, F., Astuti, G., Huynen, M. A., van Wijk, E., Stieger, K., & Collin, R. W. J. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.04.004 · Cited by 135
“Following several studies with sometimes contradictory results, it seems that AAV serotype 9 may be the most efficient vector to target photoreceptors (both rods and cones) and RPE cells following subretinal injection (Vandenberghe et al., 2013).”
ResultThe primate model for understanding and restoring vision
Picaud, S., Dalkara, D., Marazova, K., Goureau, O., Roska, B., & Sahel, J.-A. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902292116 · Cited by 113
“Based on these studies, AAV9 and its variants have been shown to lead to efficient foveal cone transduction when injected into the subretinal space (20, 98).”
BackgroundMethodGaranto, A., Chung, D. C., Duijkers, L., Corral-Serrano, J. C., Messchaert, M., Xiao, R., Bennett, J., Vandenberghe, L. H., & Collin, R. W. J. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw118 · Cited by 110
“Nevertheless, in order to have the optimal vector for the studies in our fibroblast model, AAV2/2 was selected for the generation of the AON-containing vectors.”
BackgroundSelf-citationPatterning and Development of Photoreceptors in the Human Retina
Hussey, K. A., Hadyniak, S. E., & Johnston, R. J. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.878350 · Cited by 125
“Additionally, non-human primates are amenable to genetic manipulations including CRISPR (Kang et al., 2019), optogenetics (Chaffiol et al., 2017), adeno-associated virus (AAV) (Vandenberghe et al., 2013), and transplants (Picaud et al., 2019).”
Efficient gene delivery to the cone-enriched pig retina by dual AAV vectors
Colella, P., Trapani, I., Cesi, G., Sommella, A., Manfredi, A., Puppo, A., Iodice, C., Rossi, S., Simonelli, F., Giunti, M., et al. (2014) · Gene Therapy · doi:10.1038/gt.2014.8 · Cited by 103
Buck, T., & Wijnholds, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124197 · Cited by 92
“rAAV8BP2, rAAV9 and rAAV5 infect cone photoreceptors more efficiently than rAAV2 [318,319,321].”
BackgroundTakahashi, K., Igarashi, T., Miyake, K., Kobayashi, M., Yaguchi, C., Iijima, O., Yamazaki, Y., Katakai, Y., Miyake, N., Kameya, S., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.008 · Cited by 99
“Moreover, several adverse effects, including foveal thinning, macular holes, choroidal effusion, and ocular hypo- or hypertension have been observed during the immediate postoperative days.(2,3,8,9) Consequently, subretinal injection can potentially lead to permanent visual dysfunction.”
BackgroundQuinn, P. M., Buck, T. M., Mulder, A. A., Ohonin, C., Alves, C. H., Vos, R. M., Bialecka, M., van Herwaarden, T., van Dijk, E. H. C., Talib, M., et al. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.03.002 · Cited by 97
“AAV5 and AAV9 infect non-human primate rod and cone photoreceptors (Boye et al., 2012; Vandenberghe et al., 2013).”
BackgroundThe non-human primate experimental glaucoma model
Burgoyne, C. F. (2015) · Experimental Eye Research · doi:10.1016/j.exer.2015.06.005 · Cited by 91
Organoids and organ chips in ophthalmology
Manafi, N., Shokri, F., Achberger, K., Hirayama, M., Mohammadi, M. H., Noorizadeh, F., Hong, J., Liebau, S., Tsuji, T., Quinn, P. M. J., et al. (2020) · The Ocular Surface · doi:10.1016/j.jtos.2020.11.004 · Cited by 87
AAV-Mediated Gene Delivery to 3D Retinal Organoids Derived from Human Induced Pluripotent Stem Cells
Garita-Hernandez, M., Routet, F., Guibbal, L., Khabou, H., Toualbi, L., Riancho, L., Reichman, S., Duebel, J., Sahel, J.-A., Goureau, O., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030994 · Cited by 82
“Similarly, rAAV9 gave rise to poor transduction in our retinal organoids despite being highly successful in targeting cones in mice and nonhuman primates [25,30].”
BackgroundOptimization of Retinal Gene Therapy for X-Linked Retinitis Pigmentosa Due to RPGR Mutations
Beltran, W. A., Cideciyan, A. V., Boye, S. E., Ye, G.-J., Iwabe, S., Dufour, V. L., Marinho, L. F., Swider, M., Kosyk, M. S., Sha, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.004 · Cited by 82
“Should higher levels of the therapeutic transgene be required in cones, this potential limitation may be circumvented by using AAV capsid serotypes reported to have improved tropism to NHP cones than that of AAV2/5.33,34 However, on the basis of our prior experience with AAV2/5’s ability to infect canine rods and cone…”
BackgroundInfluentialBoye, S. L., Bennett, A., Scalabrino, M. L., McCullough, K. T., Van Vliet, K., Choudhury, S., Ruan, Q., Peterson, J., Agbandje-McKenna, M., & Boye, S. E. (2016) · Journal of Virology · doi:10.1128/jvi.00200-16 · Cited by 79
Highly Efficient Delivery of Adeno-Associated Viral Vectors to the Primate Retina
Boye, S. E., Alexander, J. J., Witherspoon, C. D., Boye, S. L., Peterson, J. J., Clark, M. E., Sandefer, K. J., Girkin, C. A., Hauswirth, W. W., & Gamlin, P. D. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.085 · Cited by 78
Advances in gene therapy technologies to treat retinitis pigmentosa
Petrs-Silva, H., & Linden, R. (2013) · Clinical Ophthalmology · doi:10.2147/opth.s38041 · Cited by 74
“27 31 In several species, including primates, serotype 4 was shown to effectively target RPE.”
Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A., Sahel, J., & Dalkara, D. (2016) · Biotechnology and Bioengineering · doi:10.1002/bit.26031 · Cited by 71
“…non-human primate retina since AAV9 has higher cone photoreceptor tropism than AAV2 and this cell type is of interest for gene therapy applications (Vandenberghe et al., 2013). r In our study 7m8 was made at the 575 position, which likely hampered sialic acid binding region and was detrimental to…”
BackgroundA long-term efficacy study of gene replacement therapy for RPGR-associated retinal degeneration
Wu, Z., Hiriyanna, S., Qian, H., Mookherjee, S., Campos, M. M., Gao, C., Fariss, R., Sieving, P. A., Li, T., Colosi, P., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv134 · Cited by 69
“The mouse Rpgr-ORF15 vector was also packaged into AAV type 9 (hereafter referred to as AAV9mRpgr), a serotype that transduces cones of non-human primate efficiently (41).”
The retinal phenotype of Usher syndrome: Pathophysiological insights from animal models
El-Amraoui, A., & Petit, C. (2014) · Comptes Rendus Biologies · doi:10.1016/j.crvi.2013.12.004 · Cited by 82
Retinal gene delivery by adeno-associated virus (AAV) vectors: Strategies and applications
Schön, C., Biel, M., & Michalakis, S. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.01.009 · Cited by 77
“in different species including mice, pigs, dogs and non-human primates [20,30,36,42–44].”
BackgroundVectors and Gene Delivery to the Retina
Planul, A., & Dalkara, D. (2017) · Annual Review of Vision Science · doi:10.1146/annurev-vision-102016-061413 · Cited by 67
“AAV serotypes 2, 5, 6, 7, 8, and 9 and engineered variants AAV2–7m8 and AAV8BP2 all allow efficient photoreceptor gene delivery (Allocca et al. 2007; Boye et al. 2012; Vandenberghe et al. 2011, 2013).”
BackgroundAdeno-Associated Viral Gene Therapy for Inherited Retinal Disease
Ong, T., Pennesi, M. E., Birch, D. G., Lam, B. L., & Tsang, S. H. (2019) · Pharmaceutical Research · doi:10.1007/s11095-018-2564-5 · Cited by 78
Carvalho, L. S., Xiao, R., Wassmer, S. J., Langsdorf, A., Zinn, E., Pacouret, S., Shah, S., Comander, J. I., Kim, L. A., Lim, L., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.154 · Cited by 63
“Previous studies have shown that both AAV8 and AAV9 are capable of targeting cone photoreceptors at similar levels in the murine retina(22) but AAV9 is substantially better than AAV8 at transducing cones in the NHP retina.(50) Figure 4A shows the colocalization of GFP positive injected areas of the retina with the mam…”
BackgroundMethodResultInfluentialSelf-citationBiophysical Properties of Optogenetic Tools and Their Application for Vision Restoration Approaches
Klapper, S. D., Swiersy, A., Bamberg, E., & Busskamp, V. (2016) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2016.00074 · Cited by 63
“The infected cells mostly cluster around the foveal rim (Vandenberghe et al., 2013).”
BackgroundRetinal transduction profiles by high-capacity viral vectors
Puppo, A., Cesi, G., Marrocco, E., Piccolo, P., Jacca, S., Shayakhmetov, D. M., Parks, R. J., Davidson, B. L., Colloca, S., Brunetti-Pierri, N., et al. (2014) · Gene Therapy · doi:10.1038/gt.2014.57 · Cited by 56
Pénzes, J. J., Chipman, P. R., Bhattacharya, N., Zeher, A., Huang, R. K., McKENNA, R. V., & Agbandje‐McKenna, M. (2021) · Journal of Virology · doi:10.1128/jvi.00843-21 · Cited by 57
The Future Looks Brighter After 25 Years of Retinal Gene Therapy
Auricchio, A., Smith, A. J., & Ali, R. R. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.164 · Cited by 52
“Subsequently, many more naturally occurring 7–9 or engineered 10,11 AAV serotypes have been assessed for their ability to transduce the retina, with the aim of identifying serotypes with advantageous properties: different cell tropisms, a greater ability to penetrate the inner retina, or to mediate…”
Grotz, S., Schäfer, J., Wunderlich, K. A., Ellederová, Z., Auch, H., Bähr, A., Vochozková, P., Fadl, J., Arnold, V., Ardan, T., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202114817 · Cited by 52
Self-citationPromising and delivering gene therapies for vision loss
Carvalho, L. S., & Vandenberghe, L. H. (2015) · Vision Research · doi:10.1016/j.visres.2014.07.013 · Cited by 49
Self-citationSubILM Injection of AAV for Gene Delivery to the Retina
Gamlin, P. D., Alexander, J. J., Boye, S. L., Witherspoon, C. D., & Boye, S. E. (2019) · Methods in Molecular Biology · doi:10.1007/978-1-4939-9139-6_14 · Cited by 46
Delivering AAV to the Central Nervous and Sensory Systems
Peters, C. W., Maguire, C. A., & Hanlon, K. S. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.03.004 · Cited by 45
Combined Rod and Cone Transduction by Adeno-Associated Virus 2/8
Manfredi, A., Marrocco, E., Puppo, A., Cesi, G., Sommella, A., Della Corte, M., Rossi, S., Giunti, M., Craft, C. M., Bacci, M. L., et al. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.154 · Cited by 43
Current advances in gene therapy of mitochondrial diseases
Soldatov, V. O., Kubekina, M. V., Skorkina, M. Y., Белых, А. Е., Egorova, T. V., Корокин, М. В., Pokrovskiy, M. V., Deykin, A. V., & Angelova, P. R. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03685-0 · Cited by 48
Simpson, E. M., Korecki, A. J., Fornés, O., McGill, T. J., Vargas, J. L. C., Agostinone, J., Farkas, R. A., Hickmott, J. W., Lam, S. L., Mathelier, A., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.118 · Cited by 43
“21 Here we explored the rAAV9 capsid, which has not been used clinically for the eye and has no previous evidence for targeting primate RGCs 22 but is in clinical trial in the brain.”
Optimized Adeno-Associated Virus Vectors for Efficient Transduction of Human Retinal Organoids
Völkner, M., Pavlou, M., Büning, H., Michalakis, S., & Karl, M. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.321 · Cited by 42
“17 23 Among the best performing serotypes, AAV9 is known to have high tropism for the central nervous system, 24,25 including the retina, 22,26,27 which prompted us to focus on this serotype in our study.”
Holthaus, S.-M. K., Aristorena, M., Maswood, R. N., Semenyuk, O., Hoke, J., Hare, A., Smith, A. J., Mole, S., & Ali, R. R. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.038 · Cited by 42
“Of note is that the current CNS-directed gene therapy clinical trial for CLN3 disease uses AAV2/9, an AAV serotype similar to AAV2/8 transduces photoreceptors and the RPE well, yet does not target cells in the inner retina.(41) In line with other reports,(12,13) we did not observe any reduction in photoreceptor functi…”
BackgroundTeo, K. Y. C., Lee, S. Y., Barathi, A. V., Tun, S. B. B., Tan, L., & Constable, I. J. (2018) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.18-24333 · Cited by 33
“This method has been proven in animal models and early clinical trials to effectively transfect the RPE cells(4) and the photoreceptors.(20,21) This method of delivery, while effective, has several shortcomings.”
MethodMühlfriedel, R., Tanimoto, N., Schön, C., Sothilingam, V., Garrido, M. G., Beck, S. C., Huber, G., Biel, M., Seeliger, M. W., & Michalakis, S. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00292 · Cited by 36
“, 2013), and AAV2/9 (Vandenberghe et al., 2013) were found to present the highest cone transduction properties.”
BackgroundInfluentialNovel AAV44.9-Based Vectors Display Exceptional Characteristics for Retinal Gene Therapy
Boye, S. L., Choudhury, S., Crosson, S., Di Pasquale, G., Afione, S., Mellen, R., Makal, V., Calabro, K. R., Fajardo, D., Peterson, J., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.04.002 · Cited by 29
“9(E531D) mediated efficient expression of the transgene in macaque parafoveal and perifoveal cones, cells that have been refractory to transduction by other AAV vectors.(13) Additionally when tested in a mouse model of LCA, AAV44.”
BackgroundInfluentialGene therapy for inherited retinal degenerations: initial successes and future challenges
Gupta, P. R., & Huckfeldt, R. M. (2017) · Journal of Neural Engineering · doi:10.1088/1741-2552/aa7a27 · Cited by 29
Clérin, E., Marussig, M., Sahel, J., & Léveillard, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051625 · Cited by 33
“Thioredoxin RdCVFL acts in a cell-autonomous manner of photoreceptors, so the potent serotypes are those reported to transduce cones in the case of RP, as serotypes 5, 8, and 9 [111,142,143].”
BackgroundLeber Congenital Amaurosis Caused by Mutations in GUCY2D
Boye, S. L. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017350 · Cited by 26
“Only partial cone transduction was achieved following subretinal delivery of elevated doses of AAV8-CMV-GFP (1011 vg de- livered) in nonhuman primates (Vandenberghe et al. 2011, 2013).”
BackgroundPetit, L., Ma, S., Cheng, S.-Y., Gao, G., & Punzo, C. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.020 · Cited by 24
“20 30–34 In particular, injection of AAV2/8 at postnatal day (PND) 0 results primarily in cone transduction ( * 100% of cones, almost no rods), 32–34 whereas the vast majority of transduced cells in adults are rods.”
Koponen, S., Kokki, E., Tamminen, T., & Ylä-Herttuala, S. (2023) · Frontiers in Drug Delivery · doi:10.3389/fddev.2023.1148795 · Cited by 21
Argyriou, C., Polosa, A., Song, J. Y., Omri, S., Steele, B. H., Cécyre, B., McDougald, D. S., Pietro, E. D., Bouchard, J., Bennett, J., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.09.002 · Cited by 21
Self-citationCone synapses in mammalian retinal rod bipolar cells
Pang, J., Yang, Z. R., Jacoby, R. A., & Wu, S. M.-S. (2018) · The Journal of Comparative Neurology · doi:10.1002/cne.24456 · Cited by 24
“It specifically labeled cones as previously reported (Blanks & Johnson, 1984; Wassle et al., 2009; Vandenberghe et al., 2013).”
BackgroundGene Therapy in Corneal Transplantation
Qazi, Y., & Hamrah, P. (2013) · Seminars in Ophthalmology · doi:10.3109/08820538.2013.825297 · Cited by 19
Developing Non-Human Primate Models of Inherited Retinal Diseases
Seah, I. Y. J., Goh, D., Chan, H. W., & Su, X. (2022) · Genes · doi:10.3390/genes13020344 · Cited by 17
“AAV serotype 9 may be the most efficient vector to target both rod and cone photoreceptors and RPE cells via subretinal injection [71].”
BackgroundNikonov, S. S., Aravand, P., Lyubarsky, A., Nikonov, R., Luo, A. J., Wei, Z., Maguire, A. M., Phelps, N. T., Shpylchak, I., Willett, K. L., et al. (2022) · Translational Vision Science & Technology · doi:10.1167/tvst.11.5.24 · Cited by 16
Self-citationProceedings of the First International Optogenetic Therapies for Vision Symposium
Francis, P. J., Mansfield, B. C., & Rose, S. (2013) · Translational Vision Science & Technology · doi:10.1167/tvst.2.7.4 · Cited by 18
“A number of AAV serotypes transduce photoreceptor cells efficiently when delivered subretinally, for example AAV2, AAV5, and AAV9.(59) AAV2 vectors are currently being employed in human clinical trials.”
BackgroundMaddalena, A., Dell'Aquila, F., Giovannelli, P., Tiberi, P., Wanderlingh, L. G., Montefusco, S., Tornabene, P., Iodice, C., Visconte, F., Carissimo, A., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.220 · Cited by 16
“9–15 However, the relatively small DNA packaging capacity of AAV, which is considered to be restricted to the size of the parental genome (4.7kb), 16–19 prevents their application from the treatment of those diseases caused by mutations in genes having a coding sequence (CDS) > 5kb.”
Riaz, S., Sethna, S., Duncan, T. E., Naeem, M. A., Redmond, T. M., Riazuddin, S. A., Riazuddin, S., Carvalho, L. S., & Ahmed, Z. M. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.10.017 · Cited by 15
Hori, T., Fukutome, M., & Koike, C. (2019) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b18-00913 · Cited by 16
Insights gained from gene therapy in animal models of retGC1 deficiency
Boye, S. L. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00043 · Cited by 16
Ross, M., Obolensky, A., Averbukh, E., Desrosiers, M., Ezra-Elia, R., Honig, H., Yamin, E., Rosov, A., Dvir, H., Gootwine, E., et al. (2022) · Gene Therapy · doi:10.1038/s41434-021-00306-1 · Cited by 13
“For targeting cones in primates, it has been suggested that AAV9 is the most permissive naturally occurring serotype based on studies injecting this capsid directly under the macaque fovea [40].”
BackgroundDay, T. P., Byrne, L. C., Flannery, J. G., & Schaffer, D. V. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7522-8_17 · Cited by 12
Schwartz, M. K., Likhite, S. B., Vetter, T. A., Baird, M., McGovern, V. L., Sierra-Delgado, J. A., Mendel, T., Burghes, A. H. M., & Meyer, K. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.05.016 · Cited by 11
“As previously mentioned, one study had found that Anc80 has a higher transduction efficiency, compared with AAV9 after subretinal injection, within cone photoreceptors and the RPE in both mice and NHPs.(47) This previous study utilized single-stranded vector constructs with the CMV promoter.”
ResultLa conception de vecteurs adaptés à la thérapie génique oculaire
Khabou, H., & Dalkara, D. (2015) · médecine/sciences · doi:10.1051/medsci/20153105015 · Cited by 17
Minella, A., Mowat, F. M., Willett, K. L., Sledge, D. G., Bartoe, J. T., Bennett, J., & Petersen‐Jones, S. M. (2014) · Gene Therapy · doi:10.1038/gt.2014.65 · Cited by 9
“22 Also similar to our findings, a study investigating rAAV2/5 and 2/8 transduction showed both rod and cone transduction in the high cone/rod ratio porcine retina at comparable doses.”
Self-citationHinsch, V. G., Boye, S. L., & Boye, S. E. (2025) · Human Gene Therapy · doi:10.1089/hum.2024.252 · Cited by 13
Novel Methodology for Creating Macaque Retinas with Sortable Photoreceptors and Ganglion Cells
Choudhury, S., Strang, C. E., Alexander, J. J., Scalabrino, M. L., Hill, J. L., Kasuga, D. T., Witherspoon, C. D., Boye, S. L., Gamlin, P. D., & Boye, S. L. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00551 · Cited by 9
Optogenetics and prosthetic treatment of retinal degeneration
Kirpichnikov, M. P., & Ostrovskiy, M. A. (2015) · Russian Annals of Ophthalmology · doi:10.17116/oftalma2015131399-111 · Cited by 7
“Вместе с тем и несколько других серотипов аденоассоциированных вирусов, например AAV5 и AAV9, как недавно показано, способны эффективно доставить ген в фоторецепторные клетки (колбочки) у приматов [46].”
Vendomèle, J., Chauveau, G. A., Dalkara, D., Galy, A., & Fisson, S. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.191 · Cited by 6
Correcting visual loss by genetics and prosthetics
Xue, K., & MacLaren, R. E. (2020) · Current Opinion in Physiology · doi:10.1016/j.cophys.2020.03.003 · Cited by 5
Organoid transduction using recombinant adeno‐associated viral vectors: Challenges and opportunities
Belova, L., Лавров, А. В., & Smirnikhina, S. (2022) · BioEssays · doi:10.1002/bies.202200055 · Cited by 6
Schön, C., Bećirović, E., Biel, M., & Michalakis, S. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7522-8_3 · Cited by 6
Kelley, R. A., & Wu, Z. (2023) · Vision Research · doi:10.1016/j.visres.2023.108269 · Cited by 5
Optogenetik – eine Chance für fortgeschrittene retinale Dystrophien
Swiersy, A., Klapper, S. D., & Busskamp, V. (2017) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/s-0043-101820 · Cited by 3
AAV-Mediated Gene Therapy for CRB1-Hereditary Retinopathies
Alves, C. H., & Wijnholds, J. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.79308 · Cited by 5
“Subretinal injection of expression vectors packaged into serotypes AAV5 or AAV9 infect photoreceptors in vivo in macaques [82, 83].”
BackgroundGene Therapy for Retinal Disease
Bennett, J., & Maguire, A. M. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0737-9.00034-5 · Cited by 2
Self-citationGene Therapy for Dominantly Inherited Retinal Degeneration
Farrar, G. J., Millington‐Ward, S., Palfi, A., Chadderton, N., & Kenna, P. F. (2014) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-3-662-45188-5_4 · Cited by 4
Alsalloum, A., Mosin, I., Shefer, K. К., Mingaleva, N., Kim, A., Feoktistova, S. G., Malyugin, B. E., Boiko, E. V., Sultanov, S., Mityaeva, O. N., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164592 · Cited by 2
“Additionally, macular bull’s eye patterns, hyperfluorescence anomalies, and generalized fine pigmentary retinopathy have been documented in the literature [7,8].”
BackgroundAgbim, C., Wu, H., Kim, C. J., Mutter‐Rottmayer, E., Sadekar, S., & Marković, M. (2025) · Clinical and Translational Science · doi:10.1111/cts.70428 · Cited by 1
Preparation of Nonhuman Primate Eyes for Histological Evaluation After Retinal Gene Transfer
Bell, P. L., Yu, H., Kuntz, L., Ahonkhai, O., Tretiakova, A. P., Limberis, M. P., & Wilson, J. M. (2018) · Human Gene Therapy Methods · doi:10.1089/hgtb.2018.045 · Cited by 1
Self-citationGene therapy approaches in central nervous system regenerative medicine
Bosch, A., & Chillón, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818084-6.00010-6 · Cited by 1
Michalakis, S., Gerhardt, M.-J., Priglinger, C., & Priglinger, S. G. (2021) · Springer eBooks · doi:10.1007/978-3-319-90495-5_150-1 · Cited by 1
Adeno-associated Viral Vectors in the Retina: Delivering Gene Therapy to the Right Destination
Rudnick, N. D., Kim, L. A., & Comander, J. (2022) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000416 · Cited by 1
Michalakis, S., Gerhardt, M.-J., Priglinger, C., & Priglinger, S. G. (2022) · Springer eBooks · doi:10.1007/978-3-030-42634-7_150 · Cited by 1
Opportunities and challenges of gene therapy for retinitis pigmentosa
Luo, X., Liu, Y., FengHua, W. A. N. G., & Sun, X. (2022) · Scientia Sinica Vitae · doi:10.1360/ssv-2020-0012 · Cited by 2
Gene Therapy for Leber’s Congenital Amaurosis Due to RPE65 Mutations
Bennett, J. (2014) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-3-662-45188-5_2 · Cited by 1
Self-citationWei, Z., Liu, X., Li, T., Li, X., Zhou, Q., Wu, J., & Zhang, C. (2021) · Future Virology · doi:10.2217/fvl-2020-0096
Kick, G. R. (2021) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/88127
Vendomèle, J., Chauveau, G. A., Dalkara, D., Galy, A. H. M., & Fisson, S. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.30.522324
Organoid-based modality of eye function and cellular processes
El-Hashash, A. H. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99987-8.00006-0
Development of safe and efficient aav vectors for retinal gene therapy
Khabou, H. (2018) · theses.fr (ABES) · doi:10.70675/aa896663z9772z4d87z9bd1z247af1f0e3f1
Directed evolution of adeno associated virus (AAV) for retinal gene therapy
Tekinsoy, M. (2022) · theses.fr (ABES) · doi:10.70675/80e7fd11z0ae7z46ffz8f69zb50f7a34df5a
Physiological Postnatal Neurogenesis, Development, and Maturation in the Regenerable Retina
Pang, V. Y., Zhong, W., Yang, Z., Wu, S., & Pang, J. (2026) · The Journal of Comparative Neurology · doi:10.1002/cne.70212
Metadata
- Authors
- Vandenberghe, L. H., Bell, P., Maguire, A. M., Xiao, R., Hopkins, T. B., Grant, R., Bennett, J., & Wilson, J. M.
- Affiliations
- University of Pennsylvania (US)
- Corresponding author
- Vandenberghe, Luk H.
- Wilson, James M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-01-30
- Volume
- 8
- Issue
- 1
- Pages
- e53463
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3559681
- OpenAlex
- W2085736058
- Cited by
- 97
- References
- 29
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 9 · 2022: 10 · 2021: 8 · 2020: 8 · 2019: 6 · 2018: 9 · 2017: 11 · 2016: 7 · 2015: 8 · 2014: 11 · 2013: 4
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Update notices
- correction (2013-08-08)
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Foundation Fighting Blindness
- F. M. Kirby Foundation
- Research to Prevent Blindness
- GlaxoSmithKline
- University of Pennsylvania
- James N. Kirby Foundation
- National Institutes of Health (1dp1od008267-01)
- National Eye Institute (DP1EY023177)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK 47757, P30DK047757)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- AAV9, cone photoreceptors, rod photoreceptors, retinal gene therapy, subretinal injection, fovea, AAV2, AAV8
- MeSH terms
- Dependovirus, Animals, Genetic Vectors, Primates, Retina, Transduction, Genetic, Genetic Therapy, Retinal Rod Photoreceptor Cells, Retinal Cone Photoreceptor Cells, Leber Congenital Amaurosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.